Navigation Links
Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
Date:1/28/2008

ne health. Velcura develops highly differentiated therapies for bone disease; specifically, dual-acting therapies that demonstrate both bone building and anti-bone loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize these compounds. Velcura's lead compound, VEL-0230 was identified using these bone assays. More information is at http://www.velcura.com.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215


'/>"/>
SOURCE Velcura Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
2. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
3. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
4. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
5. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
6. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
7. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
8. Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes
9. ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering
10. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...HUN, China and LOS ANGELES, Nov. 30 /PRNewswire-As...c. (OTC Bulletin Board: CYXN; ,China Yongxin,Pharm...rer, distributor and,retailer of pharmaceuticals i...eted preparation for distribution of medicines on ...vernment recently formalized the nation,s Essentia...
(Date:11/30/2009)..., Nov. 30 BioMarin Pharm...at the Food and Drug Administration (FDA) has gran...e (3,4-DAP), amifampridine phosphate, for the rare...ome (LEMS). 3,4-DAP has previously received orpha...009, the Committee for Medicinal Products for Huma...
(Date:11/30/2009)..., Nov. 30 Cell Therapeut...oday that its new class of platinum-based anti-tum...a stronger anti-tumor potency and activity compare...as well as the ability to overcome cisplatin-resis...ented in a paper titled "Novel Bis-platinum Comple...
(Date:11/30/2009)...GHAI, Nov. 30 /PRNewswire-Asia/ -- WuXi PharmaTech...ology, and medical-device research and,development...the United States,announced that it had been sele... list for the fifth consecutive year. The list rec...s technology, media, and telecommunications,indust...
Breaking Biology Technology:China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2
... Svenja Goth , PerkinElmer Life and...enue , Shelton, CT 06484-4794 USA , ...ytical Sciences Department , Physical Ch...es Guesde , 94403 Vitry-sur-Seine - FRAN... Separation of transitions , Detec...
...xpression Assays average 100% efficiency (+/- 10%)...ms has designed and manufactured over 40,000 real-...nes in humans, mice, and rats. TaqMan Gene Express...forward and reverse) and a fluorescent labeled Taq... One of the major user concerns regarding any r...
... In this application note, several different ... for their merits. A comprehensive examination of ...y modes was performed to illustrate data quality a...r of metabolites were found with each mode of oper...tabolites derived from glyburide. , Overv...
Other Biology Technology:Practical Applications of HyperDSC in a Pharmaceutical Laboratory 2Practical Applications of HyperDSC in a Pharmaceutical Laboratory 3Practical Applications of HyperDSC in a Pharmaceutical Laboratory 4Practical Applications of HyperDSC in a Pharmaceutical Laboratory 5Amplification Efficiency of TaqMan Gene Expression Assays 2Amplification Efficiency of TaqMan Gene Expression Assays 3Amplification Efficiency of TaqMan Gene Expression Assays 4Amplification Efficiency of TaqMan Gene Expression Assays 5Amplification Efficiency of TaqMan Gene Expression Assays 6Amplification Efficiency of TaqMan Gene Expression Assays 7Amplification Efficiency of TaqMan Gene Expression Assays 8Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 2Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 3Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 4Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 5Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 6
(Date:11/30/2009)...ase is available in German . , The DFG has ... Research Centres as of 1 January 2010. This decis...ttee in Bonn. The new centres will initially be fu...n addition, 20 percent overhead funding for indire...he centres, research topics range from modern pros...
(Date:11/30/2009)...s of The Journal of Experimental Biology are ple... National de la Recherche Scientifique (CNRS) in t...r of this year,s JEB Outstanding Paper Prize. ,T...ng achievement and is intended to encourage young ...-in-Chief, and adds that ,we truly appreciate when...
(Date:11/30/2009)...temperatures continue to rise scientists are prese...ow species respond and adapt. In a paper published...sco Rodriguez-Trelles and Dr Miguel Rodriguez asse...rming of approximately 0.6˚C has already affe... facing ecologists and evolutionary biologists is ...
Breaking Biology News(10 mins):DFG approves funding for 17 new collaborative research centers 2DFG approves funding for 17 new collaborative research centers 3DFG approves funding for 17 new collaborative research centers 4DFG approves funding for 17 new collaborative research centers 5DFG approves funding for 17 new collaborative research centers 6DFG approves funding for 17 new collaborative research centers 7DFG approves funding for 17 new collaborative research centers 8DFG approves funding for 17 new collaborative research centers 9French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4How can scientists measure evolutionary responses to climate change? 2China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 1China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 2China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 3China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 4China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 5China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 6China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 7China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 8China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 9China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 10China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 11China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 12China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 13China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 14China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 15China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results 55099 16LASIK Eye Surgery Practice in Phoenix Arizona Giving Away Free LASIK to Winner of New Video Contest 55097 1LASIK Eye Surgery Practice in Phoenix Arizona Giving Away Free LASIK to Winner of New Video Contest 55097 2LASIK Eye Surgery Practice in Phoenix Arizona Giving Away Free LASIK to Winner of New Video Contest 55097 3ProFibrix Raises US 2411 Million 28EUR 8 million 29 in Series B Financing 13650 1ProFibrix Raises US 2411 Million 28EUR 8 million 29 in Series B Financing 13650 2ProFibrix Raises US 2411 Million 28EUR 8 million 29 in Series B Financing 13650 3
...l engineers at The University of Texas Health Scie...ion initiative to produce a bio-compatible compoun...esearchers have been awarded $5.2 million in initi...develop "fracture putty" that could be used to reg... explosive devices. This type of injury is called ...
... Through work originally designed to remove conta...nt of Energy,s (DOE) Brookhaven National Laborator...ty have identified plant-associated microbes that ...dings, published in the February 1, 2009 issue of ... scientists design strategies for sustainable biof...
...rt today that the FDA has approved the first human...tervention raises important ethical considerations... at issue is an embryonic stem cell-based interven...e ethics of embryo research surround the interest ...ing the first human trial of its kind. Any "first...
Other Biology News:UT to develop fracture putty for traumatic leg injuries 2UT to develop fracture putty for traumatic leg injuries 3UT to develop fracture putty for traumatic leg injuries 4Scientists identify bacteria that increase plant growth 2Scientists identify bacteria that increase plant growth 3
Rabbit Anti-Uncoupling Protein-2, aa 144-157 Polyclonal Antibody, Unconjugated from Calbiochem
...n translation initiation. PHAS-II is highest in li...mRNA cap-binding protein, and inhibit translation ...ion in the appropriate site(s) promotes dissociati... bind to eIF-4G (p220), thereby increasing the amo...
Human GCP-2, Unconjugated from CHEMICON
Corning Culture Flask, 150 cm2, Tc-Treated, Angled Neck, Phenolic-Style, Sterile from Sigma-Aldrich
Biology Products: